Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica Katz

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
The New England Journal of Medicine|June 3, 2015
Elotuzumab Therapy for Relapsed or Refractory Multiple MyelomaSagar Lonial, Meletios Dimopoulos, Antonio Palumbo, et al.
The New England Journal of Medicine|August 30, 2023
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple MyelomaPaul G Richardson, Suzanne Trudel, Rakesh Popat, et al.
Lancet (London, England)|June 14, 2026
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trialMeletios A Dimopoulos, Fredrik Schjesvold, Chengcheng Fu, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
The New England Journal of Medicine|June 3, 2015
Elotuzumab Therapy for Relapsed or Refractory Multiple MyelomaSagar Lonial, Meletios Dimopoulos, Antonio Palumbo, et al.
The New England Journal of Medicine|August 30, 2023
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple MyelomaPaul G Richardson, Suzanne Trudel, Rakesh Popat, et al.
Lancet (London, England)|June 14, 2026
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trialMeletios A Dimopoulos, Fredrik Schjesvold, Chengcheng Fu, et al.
Pageof 2